Skip to main content
Equibles
ATAI logo

ATAI · AtaiBeckley Inc.

Track ATAI — free

Use ATAI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ATAI

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.35 -0.04 (-0.54%) At close · Aug 27
Market Cap
$2.74B
Shares
370.86M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.35 Open$7.38 Day$7.35–7.40 52W close$3.35–7.44 Avg vol 30d10.2M Short int16.9M · 4.5% float · 2.8d Short vol18% Last earningsMar 6, 2026 DataJun 2021–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +61%
above
Price vs 50-day avg +16%
above
RSI (14) 68
neutral
MACD trend Negative
52-week position 98%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +117%
trailing
YTD return +80%
this year
Relative strength +102%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+32% holders QoQ · +85 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of float · ▼ -15.1% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
238 holders — 13F breadth
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
Revenue growth +1228%
Y/Y
EPS growth −213%
Y/Y
Free cash flow $-103.6M
Balance sheet $50.1M
net debt
Quant / Vol
risk profile
High
Volatility 79%
annualized · 1-yr
Max drawdown −48%
past year
ATR 1.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+61% Bullish
Price vs 50-day avg
+16% Bullish
RSI (14)
68 Neutral
MACD trend
Negative Bearish
52-week position
98% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+32% holders QoQ · +85 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of float · ▼ -15.1% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
238 holders — 13F breadth
Price context
position in its 52-week range
Range low $3 Now $7 · 98% Range high $7
vs 200-day avg +61% vs 50-day avg +16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Patients have at least one treatment per week as maintenance 80% maintenance —
Patients were prescribed the 84mg dose by treatment session 64% treatment session —
WAC price per 56mg $834 current —
WAC price per 84mg $1,251 current —
WAC price per device (28mg) $417 current —
~70% of Spravato® patients are on a weekly maintenance treatment 70% maintenance —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATAI
AtaiBeckley Inc.
this stock
$2.74B +79.7% +1227.6% — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +4.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
238
% held
36.8%
Net QoQ
+36.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
84
View
Short & Settlement
Short Interest Falling
Shares short
16.9M
Days to cover
2.8d
Change
-3.0M sh
View
Short Volume
Short vol %
18%
As of
Aug 27, 2026
Short Total
View
Fails to Deliver
FTD shares
476.7K
Value
$3.4M
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
53.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.1M
Net income (FY)
$-660.0M
EPS diluted
$-2.91
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 11, 2026
This year
14
View
Proposed Sales
Value
$496.0K
Shares
100.0K
Filed
Jul 7, 2026
View
Earnings & Events
Earnings Calls
Last call
Mar 6, 2026
View

Performance

5D 20D 120D MTD YTD
ATAI -0.9% +2.4% +116.8% +2.4% +79.7%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY -2.1% -1.6% +102.1% -0.9% +66.6%
Key facts CIK 2081043 CUSIP 04650F101 13F (30d) 194 filings 194 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)